Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Director | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 241,365 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Purchase · Acquired 9,037 · Balance 225,395 Row 2 · 2026-09-30 · Purchase · Acquired 15,970 · Balance 241,365 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 04:28 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 15,970 | $2.23 | $35,613.10 |
DisclosureSEC source: 0001493152-26-045400 · ownership.xml · nonDerivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,365 Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 04:28 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 9,037 | $2.15 | $19,429.55 |
DisclosureSEC source: 0001493152-26-045400 · ownership.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,395 Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 04:38 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 12,561 | $2.16 | $27,131.76 |
DisclosureSEC source: 0001493152-26-045185 · ownership.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,358 Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $2.19 Strike: $2.19 | $3,863.16 |
DisclosureSEC source: 0001493152-26-027262 · ownership.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,290 Underlying: Common Stock · 1,764 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% vesting upon one year from date of grant. Read SEC document |
| April 07, 2026 Filed Apr 7, 2026 22:27 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 40,000 | $2.03 | $81,200.00 |
DisclosureSEC source: 0001493152-26-015583 · ownership.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,797 Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 23:01 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 123,000 | $2.05 | $252,150.00 |
DisclosureSEC source: 0001493152-26-015361 · ownership.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,797 Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:06 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $3.20 Strike: $3.20 | $5,644.80 |
DisclosureSEC source: 0001641172-25-013794 · ownership.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,526 Underlying: Common Stock · 1,764 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% vesting upon one year from date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:41 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $7.05 Strike: $7.05 | $12,436.20 |
DisclosureSEC source: 0001493152-24-023209 · ownership.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 1,764 shares Expires 2034-06-05 Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:36 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.27 Strike: $0.27 | $7,968.00 |
DisclosureSEC source: 0001493152-23-016692 · ownership.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-10 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:35 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016405 · ownership.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,490 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:43 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000538 · doc4_7260.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 19:09 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon Stock | 5,000 | $1.35 | $6,767.00 |
DisclosureSEC source: 0001638599-21-000003 · doc4_6977.xml · nonDerivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693,548 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 19:09 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon Stock | 1,700 | $1.35 | $2,286.50 |
DisclosureSEC source: 0001638599-21-000003 · doc4_6977.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,548 Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000981 · doc4_6964.xml · derivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000981 · doc4_6964.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:11 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000594 · doc4_6750.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 15:20 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon Stock | 220,000 | $0.32 | $69,542.00 |
DisclosureSEC source: 0001638599-20-000313 · doc4_6603.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,498 F1 · price: Represents the average price of shares purchased at prices that ranged from $0.3111 - $0.328. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:11 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000611 · doc4_6151.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:28 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000698 · doc4_5500.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted stock units · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000025 · doc4_5176.xml · derivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1.25 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000025 · doc4_5176.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). Read SEC document |
| May 12, 2017 Filed May 12, 2017 20:11 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock | 17,200 | $3.76 | $64,672.00 |
DisclosureSEC source: 0001638599-17-000440 · doc4_4703.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,248 Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:39 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000125 · doc4_4502.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.